Clinical Trial Update: Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma [Phase 1]

View source ↗

Summary

A Phase 1 safety study evaluating the combination of interleukin-21 with ipilimumab for melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Interleukin-21 (Interleukin-21)
• Yervoy (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Melanoma | Phase 1 | Status: COMPLETED